A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): Trial in progress.

Poster Presentation | Jun 1, 2026

Author

Huls G, et al.

Congress

American Society of Clinical Oncology Annual Meeting

Chicago, Illinois | May 29 – June 2, 2026